300636 同和药业
已收盘 08-23 15:00:00
资讯
新帖
简况
同和药业:公司今年未有相关产品出货
证券之星 · 08-14
同和药业:公司今年未有相关产品出货
7月31日同和药业涨6.67%,财通资管健康产业混合A基金重仓该股
证券之星 · 07-31
7月31日同和药业涨6.67%,财通资管健康产业混合A基金重仓该股
同和药业涨6.67%,中泰证券二个月前给出“买入”评级
证券之星 · 07-31
同和药业涨6.67%,中泰证券二个月前给出“买入”评级
同和药业(300636)7月31日主力资金净卖出260.57万元
证券之星 · 07-31
同和药业(300636)7月31日主力资金净卖出260.57万元
同和药业(300636)7月23日主力资金净买入144.72万元
证券之星 · 07-23
同和药业(300636)7月23日主力资金净买入144.72万元
华安证券:给予同和药业增持评级
证券之星 · 07-23
华安证券:给予同和药业增持评级
华安证券7月23日发布研报称,给予同和药业(300636.SZ)增持评级。评级理由主要包括:1)公司以高端市场起家,以技术驱动发展;
智通财经 · 07-23
华安证券7月23日发布研报称,给予同和药业(300636.SZ)增持评级。评级理由主要包括:1)公司以高端市场起家,以技术驱动发展;
同和药业:公司二厂区一期工程共四个车间,均为多功能车间,已结项投入生产
证券之星 · 07-22
同和药业:公司二厂区一期工程共四个车间,均为多功能车间,已结项投入生产
同和药业最新公告:公司原料药通过CDE审批
证券之星 · 07-22
同和药业最新公告:公司原料药通过CDE审批
同和药业:公司提交的“阿戈美拉汀”原料药通过国家药品监督管理局药品审评中心(CDE)审批。
华尔街见闻 · 07-22
同和药业:公司提交的“阿戈美拉汀”原料药通过国家药品监督管理局药品审评中心(CDE)审批。
【同和药业(300636.SZ):阿戈美拉汀原料药通过CDE审批】智通财经APP讯,同和药业(300636.SZ)发布公告,公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉,公司提交的“阿戈美拉汀”原料药通过了CDE审批。
智通财经 · 07-22
【同和药业(300636.SZ):阿戈美拉汀原料药通过CDE审批】智通财经APP讯,同和药业(300636.SZ)发布公告,公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉,公司提交的“阿戈美拉汀”原料药通过了CDE审批。
同和药业(300636.SZ):阿戈美拉汀原料药通过CDE审批
智通财经 · 07-22
同和药业(300636.SZ):阿戈美拉汀原料药通过CDE审批
同和药业(300636)7月19日主力资金净买入83.69万元
证券之星 · 07-19
同和药业(300636)7月19日主力资金净买入83.69万元
平安证券:给予同和药业增持评级
证券之星 · 07-18
平安证券:给予同和药业增持评级
平安证券7月18日发布研报称,给予同和药业(300636.SZ)推荐评级。评级理由主要包括:1)同和药业特色原料药产品梯队完整,加速增长拐点初现;
智通财经 · 07-18
平安证券7月18日发布研报称,给予同和药业(300636.SZ)推荐评级。评级理由主要包括:1)同和药业特色原料药产品梯队完整,加速增长拐点初现;
同和药业(300636)7月15日主力资金净买入533.03万元
证券之星 · 07-15
同和药业(300636)7月15日主力资金净买入533.03万元
同和药业涨5.16%,太平洋二个月前给出“买入”评级,目标价16.50元
证券之星 · 07-05
同和药业涨5.16%,太平洋二个月前给出“买入”评级,目标价16.50元
【中泰证券:关注Q2业绩超预期 把握医药底部资产】智通财经APP获悉,中泰证券发布研报称,展望下半年,行业基本面有望从24Q3开始改善,低基数下业绩增速有望逐季回升,政策层面创新药支持政策、医疗反腐等均有望边际向好,医药板块有望迎来一波强势反弹,建议当下提前布局底部有弹性的资产。
智通财经 · 07-01
【中泰证券:关注Q2业绩超预期 把握医药底部资产】智通财经APP获悉,中泰证券发布研报称,展望下半年,行业基本面有望从24Q3开始改善,低基数下业绩增速有望逐季回升,政策层面创新药支持政策、医疗反腐等均有望边际向好,医药板块有望迎来一波强势反弹,建议当下提前布局底部有弹性的资产。
同和药业:6月27日接受机构调研,国泰基金、纽富斯投资等多家机构参与
证券之星 · 06-28
同和药业:6月27日接受机构调研,国泰基金、纽富斯投资等多家机构参与
同和药业:二季度新产品在高端市场的订单增加了1000万元左右同和药业6月27日在机构调研时表示,4月份我们说过新产品在高端市场的订单跟2023年比增量超过一个亿,本年度交货的在手订单超过1.
格隆汇 · 06-28
同和药业:二季度新产品在高端市场的订单增加了1000万元左右同和药业6月27日在机构调研时表示,4月份我们说过新产品在高端市场的订单跟2023年比增量超过一个亿,本年度交货的在手订单超过1.
暂无数据
公司概况
公司名称:
江西同和药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-03-31
主营业务:
江西同和药业股份有限公司主营业务为化学原料药和医药中间体的研发、生产和销售,主要产品方向为特色化学原料药及中间体、专利原料药中间体。公司是技术驱动型企业,连续多年研发投入占销售额的比例保持在8%-9%,多次被认定为高新技术企业,先后获批组建了“江西省特色原料药工程技术研究中心”、“国家博士后科研工作站”、“江西省企业技术中心”、“江西省博士后创新实践基地”、“江西省新药研发产教融合创新中心”等技术创新平台,具有强大的研发能力和技术创新能力。
发行价格:
14.47
{"stockData":{"symbol":"300636","market":"SZ","secType":"STK","nameCN":"同和药业","latestPrice":7.98,"timestamp":1724396610000,"preClose":8,"halted":0,"volume":2520502,"delay":0,"floatShares":364000000,"shares":422000000,"eps":0.2763,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"08-23 15:00:00","open":8.11,"high":8.11,"low":7.91,"amount":20183800,"amplitude":0.025,"askPrice":8,"askSize":4,"bidPrice":7.98,"bidSize":83,"shortable":0,"etf":0,"ttmEps":0.2763,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":8,"symbolType":"stock","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":8.8,"lowLimit":7.2,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":421527350,"pbRate":1.48,"roa":"--","roe":"1.94%","epsLYR":0.2786,"committee":-0.495822,"marketValue":3364000000,"floatMarketCap":2908000000,"peRate":28.881649,"changeRate":-0.0025,"turnoverRate":0.0069,"status":1},"requestUrl":"/m/hq/s/300636/tweets","defaultTab":"tweets","newsList":[{"id":"2459129656","title":"同和药业:公司今年未有相关产品出货","url":"https://stock-news.laohu8.com/highlight/detail?id=2459129656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459129656?lang=zh_cn&edition=full","pubTime":"2024-08-14 19:00","pubTimestamp":1723633257,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业(300636)08月14日在投资者关系平台上答复投资者关心的问题。投资者:请问贵公司每年新冠特效药中间体出货多少吨?同和药业董秘:感谢您对公司的关注!公司今年未有相关产品出货。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081400038894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2455906263","title":"7月31日同和药业涨6.67%,财通资管健康产业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455906263","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455906263?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:48","pubTimestamp":1722415730,"startTime":"0","endTime":"0","summary":"证券之星消息,7月31日同和药业涨6.67%创60日新低,收盘报8.8元,换手率1.29%,成交量4.72万手,成交额4053.72万元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共5家,其中持有数量最多的公募基金为财通资管健康产业混合A。财通资管健康产业混合A目前规模为3.45亿元,最新净值0.8038,较上一交易日下跌0.83%,近一年下跌23.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2455299906","title":"同和药业涨6.67%,中泰证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2455299906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455299906?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:48","pubTimestamp":1722415724,"startTime":"0","endTime":"0","summary":"今日同和药业涨6.67%,收盘报8.8元。2024年5月13日,中泰证券研究员祝嘉琦发布了对同和药业的研报《Q1业绩亮眼,拐点已现;新产品带来新周期》,该研报对同和药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为67.3%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华西证券的崔文亮、徐顺利。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600918","300636"],"gpt_icon":0},{"id":"2455925974","title":"同和药业(300636)7月31日主力资金净卖出260.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2455925974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455925974?lang=zh_cn&edition=full","pubTime":"2024-07-31 15:23","pubTimestamp":1722410622,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月31日收盘,同和药业报收于8.8元,上涨6.67%,换手率1.29%,成交量4.72万手,成交额4053.72万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:同和药业2024年一季报显示,公司主营收入2.06亿元,同比下降6.47%;归母净利润4356.28万元,同比上升31.62%;扣非净利润4048.76万元,同比上升23.31%;负债率33.01%,财务费用-556.79万元,毛利率36.67%。同和药业主营业务:化学原料药和医药中间体的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100027152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2453701447","title":"同和药业(300636)7月23日主力资金净买入144.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453701447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453701447?lang=zh_cn&edition=full","pubTime":"2024-07-23 15:31","pubTimestamp":1721719914,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月23日收盘,同和药业报收于8.6元,下跌4.23%,换手率0.77%,成交量2.82万手,成交额2462.85万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:同和药业2024年一季报显示,公司主营收入2.06亿元,同比下降6.47%;归母净利润4356.28万元,同比上升31.62%;扣非净利润4048.76万元,同比上升23.31%;负债率33.01%,财务费用-556.79万元,毛利率36.67%。同和药业主营业务:化学原料药和医药中间体的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300023851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2453794197","title":"华安证券:给予同和药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2453794197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453794197?lang=zh_cn&edition=full","pubTime":"2024-07-23 12:23","pubTimestamp":1721708585,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超近期对同和药业进行研究并发布了研究报告《品种前瞻布局享红利,产能释放助增长》,本报告对同和药业给出增持评级,当前股价为8.71元。 公司新品种在全球范围内专利陆续到期,进入快速放量期。首次覆盖,给予“增持”评级。最新盈利预测明细如下:该股最近90天内共有6家机构给出评级,买入评级4家,增持评级2家;过去90天内机构目标均价为14.59。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300020860.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","600909"],"gpt_icon":0},{"id":"2453877327","title":"华安证券7月23日发布研报称,给予同和药业(300636.SZ)增持评级。评级理由主要包括:1)公司以高端市场起家,以技术驱动发展;","url":"https://stock-news.laohu8.com/highlight/detail?id=2453877327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453877327?lang=zh_cn&edition=full","pubTime":"2024-07-23 11:27","pubTimestamp":1721705251,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["600909","300636","BK0201","BK0276","BK0239","BK0183"],"gpt_icon":0},{"id":"2453759238","title":"同和药业:公司二厂区一期工程共四个车间,均为多功能车间,已结项投入生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2453759238","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453759238?lang=zh_cn&edition=full","pubTime":"2024-07-22 17:03","pubTimestamp":1721639010,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业(300636)07月22日在投资者关系平台上答复投资者关心的问题。投资者:请问二厂区的工程完工验收了吗?什么时候正式投产?一期的正式生产了吗?二厂区一共有几个车间?多功能车间和专门车间分别有几个?同和药业董秘:感谢您对公司的关注!公司二厂区一期工程共四个车间,均为多功能车间,已结项投入生产。二期工程共七个车间,正在建设过程中。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200022893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2453755035","title":"同和药业最新公告:公司原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2453755035","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453755035?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:31","pubTimestamp":1721637073,"startTime":"0","endTime":"0","summary":"同和药业公告,公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉,公司提交的“阿戈美拉汀”原料药通过了CDE审批。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200020474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2453753793","title":"同和药业:公司提交的“阿戈美拉汀”原料药通过国家药品监督管理局药品审评中心(CDE)审批。","url":"https://stock-news.laohu8.com/highlight/detail?id=2453753793","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453753793?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:23","pubTimestamp":1721636623,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["BK0239","BK4017","300636","CDE"],"gpt_icon":0},{"id":"2453753642","title":"【同和药业(300636.SZ):阿戈美拉汀原料药通过CDE审批】智通财经APP讯,同和药业(300636.SZ)发布公告,公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉,公司提交的“阿戈美拉汀”原料药通过了CDE审批。","url":"https://stock-news.laohu8.com/highlight/detail?id=2453753642","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453753642?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:09","pubTimestamp":1721635757,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["300636","BK0239","CDE","BK4017"],"gpt_icon":0},{"id":"2453693753","title":"同和药业(300636.SZ):阿戈美拉汀原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2453693753","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453693753?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:09","pubTimestamp":1721635757,"startTime":"0","endTime":"0","summary":"智通财经APP讯,同和药业(300636.SZ)发布公告,公司近日从国家药品监督管理局药品审评中心(CDE)“原辅包登记信息公示”平台查询获悉,公司提交的“阿戈美拉汀”原料药通过了CDE审批。阿戈美拉汀适用于治疗成人抑郁症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDE","BK4017","BK0239","300636"],"gpt_icon":0},{"id":"2452483034","title":"同和药业(300636)7月19日主力资金净买入83.69万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452483034","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452483034?lang=zh_cn&edition=full","pubTime":"2024-07-19 15:23","pubTimestamp":1721373813,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月19日收盘,同和药业报收于8.77元,下跌1.79%,换手率0.83%,成交量3.02万手,成交额2650.59万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:同和药业2024年一季报显示,公司主营收入2.06亿元,同比下降6.47%;归母净利润4356.28万元,同比上升31.62%;扣非净利润4048.76万元,同比上升23.31%;负债率33.01%,财务费用-556.79万元,毛利率36.67%。同和药业主营业务:化学原料药和医药中间体的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900026784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2452512703","title":"平安证券:给予同和药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2452512703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452512703?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:30","pubTimestamp":1721284236,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,韩盟盟,臧文清近期对同和药业进行研究并发布了研究报告《传统品种业务稳健,高端市场原料药新品放量有望加速》,本报告对同和药业给出增持评级,当前股价为8.93元。同和药业营业收入稳健,2023年公司营业收入为7.22亿元,同比微增,2024Q1收入2.06亿元,同比略有下滑,主要受到下游客户去库影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800026055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","161027"],"gpt_icon":0},{"id":"2452271301","title":"平安证券7月18日发布研报称,给予同和药业(300636.SZ)推荐评级。评级理由主要包括:1)同和药业特色原料药产品梯队完整,加速增长拐点初现;","url":"https://stock-news.laohu8.com/highlight/detail?id=2452271301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452271301?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:29","pubTimestamp":1721284187,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["161027","BK0239","300636"],"gpt_icon":0},{"id":"2451969216","title":"同和药业(300636)7月15日主力资金净买入533.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451969216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451969216?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:24","pubTimestamp":1721028255,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月15日收盘,同和药业报收于8.8元,下跌6.28%,换手率2.54%,成交量9.27万手,成交额8221.55万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:同和药业2024年一季报显示,公司主营收入2.06亿元,同比下降6.47%;归母净利润4356.28万元,同比上升31.62%;扣非净利润4048.76万元,同比上升23.31%;负债率33.01%,财务费用-556.79万元,毛利率36.67%。同和药业主营业务:化学原料药和医药中间体的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500013216.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"gpt_icon":0},{"id":"2449258079","title":"同和药业涨5.16%,太平洋二个月前给出“买入”评级,目标价16.50元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449258079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449258079?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:18","pubTimestamp":1720167481,"startTime":"0","endTime":"0","summary":"今日同和药业涨5.16%,收盘报9.78元。2024年4月26日,太平洋研究员周豫,乔露阳发布了对同和药业的研报《Q1业绩超市场预期,新产品法规市场即将放量》,该研报对同和药业给出“买入”评级,认为其目标价为16.5元,现价距离目标价尚有68.71%的涨幅空间。研报中预测公司2024/25/26年营收为10.00/15.00/22.50亿元,归母净利润为2.00/3.07/4.72亿元,对应当前PE为21/14/9X,持续给予“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为68.66%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500029643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","300636"],"gpt_icon":0},{"id":"2448931788","title":"【中泰证券:关注Q2业绩超预期 把握医药底部资产】智通财经APP获悉,中泰证券发布研报称,展望下半年,行业基本面有望从24Q3开始改善,低基数下业绩增速有望逐季回升,政策层面创新药支持政策、医疗反腐等均有望边际向好,医药板块有望迎来一波强势反弹,建议当下提前布局底部有弹性的资产。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448931788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448931788?lang=zh_cn&edition=full","pubTime":"2024-07-01 10:36","pubTimestamp":1719801388,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","300636","LU0348784397.USD","000999","159992","BK0060","06978","BK0196","688076","BK0183","BK0010","BK0077","IE00B543WZ88.USD","300406","LU1720050803.USD","300705","BK1161","BK1515","688105","BK1574","BK0185","LU1794554557.SGD","600918","BK0188","605116","BK0012","002332","159938","LU0348783233.USD","BK0028","BK0046","LU0417516571.SGD","IE00B5MMRT66.SGD","SG9999014674.SGD","BK0239","BK0216","09926","159891","BK0276","BK0175","688336"],"gpt_icon":0},{"id":"2446452398","title":"同和药业:6月27日接受机构调研,国泰基金、纽富斯投资等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2446452398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446452398?lang=zh_cn&edition=full","pubTime":"2024-06-28 14:14","pubTimestamp":1719555250,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年6月28日同和药业发布公告称公司于2024年6月27日接受机构调研,国泰基金任一林、纽富斯投资杨雪香、申万宏源余玉君、东证锦信王瀚鋆参与。同和药业2024年一季报显示,公司主营收入2.06亿元,同比下降6.47%;归母净利润4356.28万元,同比上升31.62%;扣非净利润4048.76万元,同比上升23.31%;负债率33.01%,财务费用-556.79万元,毛利率36.67%。该股最近90天内共有5家机构给出评级,买入评级4家,增持评级1家;过去90天内机构目标均价为14.59。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062800025400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"gpt_icon":0},{"id":"2446354220","title":"同和药业:二季度新产品在高端市场的订单增加了1000万元左右同和药业6月27日在机构调研时表示,4月份我们说过新产品在高端市场的订单跟2023年比增量超过一个亿,本年度交货的在手订单超过1.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446354220","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446354220?lang=zh_cn&edition=full","pubTime":"2024-06-28 13:22","pubTimestamp":1719552152,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","300636"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-03-31","address":"江西省宜春市奉新县江西奉新高新技术产业园区","stockEarnings":[{"period":"1week","weight":-0.0623},{"period":"1month","weight":-0.042},{"period":"3month","weight":-0.2253},{"period":"6month","weight":0.0179},{"period":"1year","weight":-0.2443},{"period":"ytd","weight":-0.24}],"companyName":"江西同和药业股份有限公司","boardCode":"AI0027","perCapita":"24878股","boardName":"医药制造业","registeredCapital":"42152万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 江西同和药业股份有限公司主营业务为化学原料药和医药中间体的研发、生产和销售,主要产品方向为特色化学原料药及中间体、专利原料药中间体。公司是技术驱动型企业,连续多年研发投入占销售额的比例保持在8%-9%,多次被认定为高新技术企业,先后获批组建了“江西省特色原料药工程技术研究中心”、“国家博士后科研工作站”、“江西省企业技术中心”、“江西省博士后创新实践基地”、“江西省新药研发产教融合创新中心”等技术创新平台,具有强大的研发能力和技术创新能力。","serverTime":1724566783155,"listedPrice":14.47,"stockholders":"14649人(较上一季度增加7.72%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同和药业,300636,同和药业股票,同和药业股票老虎,同和药业股票老虎国际,同和药业行情,同和药业股票行情,同和药业股价,同和药业股市,同和药业股票价格,同和药业股票交易,同和药业股票购买,同和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}